US Seropositive Rheumatoid Arthritis Drug Market

ID: MRFR/Pharma/16786-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Seropositive Rheumatoid Arthritis Drug Market Research Report: By Drug Class (Nsaid, Dmards, Biologics) - Growth & Industry Forecast 2025 To 2035
US Seropositive Rheumatoid Arthritis Drug Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.37%
2024 Market Size$ 4,500 Million
2025 Market Size$ 4,741.65 Million
2035 Market Size$ 8,000 Million
Key Players
AbbVie
Roche
Pfizer
Bristol-Myers Squibb
Sanofi
Novartis
Trends
  • Personalized Medicine
  • Digital Health Integration
  • Regulatory Changes
Opportunities
  • Advancements in Biologic Therapies
  • Enhanced Patient Access to Treatments
  • Growing Demand for Combination Therapies
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Drug Class (USD Million)
      1. 4.1.1 Non-Steroidal Anti-Inflammatory Drugs
      2. 4.1.2 Disease-Modifying Anti-Rheumatic Drugs
      3. 4.1.3 Biologics
    2. 4.2 Chemicals and Materials, BY Treatment Type (USD Million)
      1. 4.2.1 Monotherapy
      2. 4.2.2 Combination Therapy
    3. 4.3 Chemicals and Materials, BY Administration Route (USD Million)
      1. 4.3.1 Oral
      2. 4.3.2 Injectable
      3. 4.3.3 Topical
    4. 4.4 Chemicals and Materials, BY Patient Age Group (USD Million)
      1. 4.4.1 Pediatric
      2. 4.4.2 Adult
      3. 4.4.3 Geriatric
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AbbVie (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bristol-Myers Squibb (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Sanofi (FR)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Novartis (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Johnson & Johnson (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Amgen (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
    5. 6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
    6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    12. 6.12 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
    14. 6.14 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
    18. 6.18 CHEMICALS AND MATERIALS, BY PATIENT AGE GROUP, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Seropositive Rheumatoid Arthritis Drug Market Segmentation

US Seropositive Rheumatoid Arthritis Drug Market By Drug Class (USD Million, 2025-2035)

  • Non-Steroidal Anti-Inflammatory Drugs
  • Disease-Modifying Anti-Rheumatic Drugs
  • Biologics

US Seropositive Rheumatoid Arthritis Drug Market By Treatment Type (USD Million, 2025-2035)

  • Monotherapy
  • Combination Therapy

US Seropositive Rheumatoid Arthritis Drug Market By Administration Route (USD Million, 2025-2035)

  • Oral
  • Injectable
  • Topical

US Seropositive Rheumatoid Arthritis Drug Market By Patient Age Group (USD Million, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.